Skip to main content

Advertisement

Table 2 Shows the serum samples for this study consists of anonymously coded vials of sera from histopathologically confirmed cases of nasopharyngeal carcinoma (NPC) and their corresponding healthy controls from studies undertaken by the National Cancer Institute, National Institutes of health, USA and detailed in manuscripts 30, 31, 32, and 40

From: Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma

Origin1 Sample Sex Age WHO [40] classification Subtype Ethnicity Ref
N M F Mean (95% CI)
Germany4 Case2 10 10 0 60.5 (50.7, 70.3) Non-keratinizing Differentiated Caucasian [31]
Control 6 5 1 NA3 Healthy   Caucasian
USA5 Case 5 3 2 60.0 (48.9, 71.2) Non-keratinizing Differentiated Caucasian [32]
Control 3 2 1 61.0 (41.2, 80.8) Healthy   Caucasian
Malaysia6 Case 12 12 0 49.5 (44.9, 54.1) Non-keratinizing Undifferentiated Asian [29, 41]
Control 4 4 0 50.0 (39.6, 60.4) Healthy   Asian
Total Case 27 25 2 52.1 (47.8, 56.3) -- -- -- --
Control 13 11 2 53.7 (43.8, 64.1) -- -- --
  1. The samples were maintained under Good Biobanking Practices at the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, Frederick, MD, National Institutes of Health, USA.
  2. 1All specimens biobanked and received from the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, National Institute of Health, USA.
  3. 2The term “case” refers to histologically confirmed nasopharyngeal carcinoma.
  4. 3NA indicates an absence of data for this group.
  5. 4Ear Nose and Throat Clinic, Cologne University, Germany.
  6. 5North American NPC Study, Mayo Clinic, USA.
  7. 6Institute of Radiotherapy, Oncology and Nuclear Medicine at the General Hospital, Kuala Lumpur, Malaysia.